KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

医学 内科学 肿瘤科 表阿霉素 安慰剂 乳腺癌 蒽环类 彭布罗利珠单抗 化疗 胃肠病学 新辅助治疗 癌症 泌尿科 病理 免疫疗法 替代医学
作者
Fátima Cardoso,Aditya Bardia,Fabrice André,David W. Cescon,Heather L. McArthur,Melinda L. Telli,Sherene Loi,Javier Cortés,Peter Schmid,Nadia Harbeck,Carsten Denkert,Christian Jackisch,Liyi Jia,Kim M. Hirshfield,Vassiliki Karantza
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (15_suppl): TPS601-TPS601 被引量:26
标识
DOI:10.1200/jco.2019.37.15_suppl.tps601
摘要

TPS601 Background: Although ER+/HER2− breast cancer (BC) has better overall prognosis than other subtypes, a high-risk subpopulation is characterized by high-grade tumors, decreased sensitivity to endocrine therapy (ET), higher responsiveness to chemotherapy (CT), and worse prognosis. Based on prior studies, increased pathological complete response (pCR) rates after neoadjuvant CT may have a substantial impact for patients with high-risk, early-stage HR+/HER2− BC. KEYNOTE-756 (ClinicalTrials.gov, NCT03725059) is a global, randomized, double-blind, phase 3 study of pembrolizumab (vs placebo) + CT as neoadjuvant treatment followed by pembrolizumab (vs placebo) + ET as adjuvant treatment for patients with high-risk, early-stage ER+/HER2− BC. Methods: Patients with T1c-2 cN1-2 (tumor size ≥2 cm) or T3-4 cN0-2 grade 3, invasive, ductal ER+/HER2− BC will be stratified by lymph node involvement (positive vs negative), tumor PD-L1 status (positive [CPS≥1] vs negative [CPS < 1]), ER positivity (ER+ ≥10% vs ER+ < 10%), and anthracycline dosing schedule (every 3 weeks [Q3W] vs Q2W), then randomized 1:1 to neoadjuvant treatment with pembrolizumab 200 mg Q3W or placebo combined with paclitaxel (80 mg/m 2 Q1W) for 4 cycles followed by doxorubicin (60 mg/m 2 ) or epirubicin (100 mg/m 2 ), each with cyclophosphamide (600 mg/m 2 ) Q2/3W for 4 cycles. After definitive surgery (± radiation therapy, as indicated), patients will receive adjuvant treatment of pembrolizumab (200 mg Q3W) or placebo for 9 more administrations combined with ET, which can be given for up to 10 years. There will be no crossover between treatment arms when moving from neoadjuvant to adjuvant treatment. Dual primary endpoints are pCR rate (ypT0/Tis ypN0) and event-free survival (EFS). Secondary endpoints include ypT0/Tis and ypT0 ypN0 pCR rates in all patients and all 3 pCR definitions in those with PD-L1+ tumors, EFS in patients with PD-L1+ tumors, overall survival, safety, and health-related quality of life. Interim analyses are planned. Enrollment is currently ongoing. Clinical trial information: NCT03725059.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
mw发布了新的文献求助10
1秒前
1秒前
黄俊完成签到,获得积分10
2秒前
sdl发布了新的文献求助10
2秒前
Darcy发布了新的文献求助10
3秒前
3秒前
3秒前
迷路的傲南完成签到,获得积分10
3秒前
坚强孤容发布了新的文献求助10
3秒前
霸气安筠完成签到,获得积分10
3秒前
一心想出文章完成签到,获得积分10
4秒前
4秒前
斯文钢笔完成签到,获得积分10
4秒前
5秒前
幽默的问梅完成签到,获得积分10
5秒前
5秒前
5秒前
酷波er的应助被阿业采纳,获得10
6秒前
6秒前
大模型的应助被wyc采纳,获得10
6秒前
无问西东给WYL的求助进行了留言
7秒前
拼搏一曲完成签到,获得积分10
7秒前
顺利毕业发布了新的文献求助10
7秒前
ggb发布了新的文献求助10
7秒前
TT完成签到,获得积分10
8秒前
姜海绵发布了新的文献求助10
8秒前
8秒前
8秒前
thisky发布了新的文献求助30
8秒前
秋风的应助被老迟到的越泽采纳,获得20
9秒前
9秒前
Ray发布了新的文献求助10
10秒前
10秒前
小荀完成签到,获得积分10
10秒前
10秒前
今后的应助被qin202569采纳,获得10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124